RSV Vaccine Side Effects
RSV Vaccines
RSV vaccines help prevent serious complications from the virus. The CDC recommends the RSV vaccine for everyone aged 75 and older and for people who are pregnant. Adults ages 60 to 74 who are at increased risk of severe RSV should also get vaccinated. That includes people who have a chronic illness such as heart disease or if you live in a nursing home.
How RSV Vaccines Work
The vaccines are single-dose, meaning you only need one shot to prevent illness. Unlike some vaccines that contain a small amount of a live virus, RSV vaccines only contain inactive proteins that help your body recognize and fight the virus. Because of this, you won’t get RSV from the shot.
Safety and Side Effects
Common side effects include pain at the injection site, headache, and fatigue. Muscle aches, joint pain, or tiredness may also occur. Serious side effects are rare but can include Guillain-Barré syndrome, a nervous system condition that causes muscle weakness or paralysis.
RSV Monoclonal Antibody for Infants
While there’s no RSV vaccine for children, they can receive a monoclonal antibody treatment. This treatment provides direct antibodies to help infants fight off RSV.
Photo Credit: ben bryant/Shutterstock
SOURCES:
Mayo Clinic: “Respiratory syncytial virus (RSV).”
CDC: “Respiratory Syncytial Virus (RSV) Vaccine,” “Frequently Asked Questions About RSV Immunization with Monoclonal Antibody for Children 19 Months and Younger,” “Frequently Asked Questions About RSV Vaccine for Adults,” “Overview of Moderna’s Investigational RSV Vaccine (mRNA-1345) in Adults ≥ 60 Years of Age,” “How to Get Your Flu, COVID-19, and RSV Vaccines This Year,” “Respiratory Syncytial Virus (RSV) Immunizations,” “Healthcare Providers: RSV Vaccination for Pregnant People,” “CDC Vaccine Price List,” “Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over,” “Respiratory Syncytial Virus (RSV) Vaccine VIS,” “RSV Vaccination for Older Adults 60 Years of Age and Over.”
Memorial Sloan Kettering Cancer Center: “What To Know About the RSV Vaccines: Who Can Get It, Side Effects, Availability at MSK.”
Yale Medicine: “Should You Get the New RSV Vaccine?”
Children’s Hospital of Philadelphia: “A Look at Each Vaccine: Respiratory Syncytial Virus (RSV) Vaccine and Monoclonal Antibody.”
American Academy of Pediatrics: “Is the RSV immunization available for infants?”
Pfizer: “Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease.”
GSK: “GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk.”
American Academy of Family Physicians: “Pregnancy and RSV.”
OSF HealthCare: “RSV's impact on your baby.”
New England Journal of Medicine: “RSV Prefusion F Protein–Based Maternal Vaccine — Preterm Birth and Other Outcomes,” “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.”
Johns Hopkins Bloomberg School of Public Health: “Two New RSV Products to Protect Infants.”
U.S. Centers for Medicare and Medicaid Services: “Respiratory Syncytial Virus (RSV) Shot.”
Yale School of Public Health: “RSV Vaccines Would Greatly Reduce Illness if Implemented Like Flu Shots.”
KFF Health News: “Timing and Cost of New Vaccines Vary by Virus and Health Insurance Status.”
Medscape: “Risk for Preterm Birth Stops Maternal RSV Vaccine Trial.”
Moderna: “Moderna Announces Update on Investigational RSV Vaccine,” “Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults.”
MedlinePlus: “What are mRNA vaccines and how do they work?” “Respiratory Syncytial Virus Infections.”
Arexvy (GSK) US Medication Guide, May 2023.
NEJM: “Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.”
Clinical Infectious Diseases: “Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial.”
Journal of Infectious Diseases: “Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.”
Open Forum Infectious Diseases: “Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons.”
CDC: "Vaccine Recommendations and Guidelines of the ACIP," "Older Adults are at High Risk for Severe RSV Illness."